Vmbook Online ordering

Macrogenics Inc

Macrogenics, Inc. is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol "MGNX." The company is a biotechnology company that focuses on the development and commercialization of innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company's pipeline includes several product candidates in various stages of clinical development, including Margetuximab, which is in phase 3 clinical trials for the treatment of breast cancer. The company has a partnership with Roche/Genentech for the development and commercialization of Margetuximab. Other product candidates include MGD013, in phase 1 clinical trials for the treatment of B-cell malignancies, and MGD019, in phase 1 clinical trials for the treatment of autoimmune diseases. Macrogenics, Inc. is based in Rockville, Maryland.